Microbiome-Competitive Landscape, Technology and Pipeline Analysis, 2017
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “Microbiome-Competitive Landscape, Technology and Pipeline Analysis, 2016”, report provides comprehensive insights about pipeline drugs across this microbiome based products. This report provides information on the therapeutic development based on the Microbiome dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information.
There are total 73 drugs in pipeline out of which 2 products is in Phase II/III, 8 products in Phase II, 6 product are in Phase I, 1 product are in Phase 0 and 1 Product in IND. Around 34 products are in Pre-clinical, 18 products are in Discovery stage of development and 3 products is in Unknown stage of development. Companies have also gone in collaboration with different partners.
The market of microbiome therapies is progressing rapidly. Various companies are getting on the action, aiming to target microbes to treat various types of diseases. Synlogic is currently developing 6 drugs that address disease by targeting gut microbiome using their synthetic biotics approach. The company is also collaborated with different partners to apply their platform to create innovative synthetic biotics for the treatment of major diseases in disease areas including inflammation, metabolism, oncology and CNS. All products of Synlogic are in Pre-Clinical and Discovery stage. Other companies are also in race for developing the products that target the microbes. Seres therapeutics is also developing the 5 products with their lead program, SER-109 for the prevention of recurrent Clostridium difficile infections, which has granted the Breakthrough therapy by FDA.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.
Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Please note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated therapy.
DelveInsight’s, “Microbiome-Competitive Landscape, Technology and Pipeline Analysis, 2016”, report provides comprehensive insights about pipeline drugs across this microbiome based products. This report provides information on the therapeutic development based on the Microbiome dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information.
There are total 73 drugs in pipeline out of which 2 products is in Phase II/III, 8 products in Phase II, 6 product are in Phase I, 1 product are in Phase 0 and 1 Product in IND. Around 34 products are in Pre-clinical, 18 products are in Discovery stage of development and 3 products is in Unknown stage of development. Companies have also gone in collaboration with different partners.
The market of microbiome therapies is progressing rapidly. Various companies are getting on the action, aiming to target microbes to treat various types of diseases. Synlogic is currently developing 6 drugs that address disease by targeting gut microbiome using their synthetic biotics approach. The company is also collaborated with different partners to apply their platform to create innovative synthetic biotics for the treatment of major diseases in disease areas including inflammation, metabolism, oncology and CNS. All products of Synlogic are in Pre-Clinical and Discovery stage. Other companies are also in race for developing the products that target the microbes. Seres therapeutics is also developing the 5 products with their lead program, SER-109 for the prevention of recurrent Clostridium difficile infections, which has granted the Breakthrough therapy by FDA.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.
Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Please note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated therapy.
Executive Summary
Executive Summary Snapshot
Microbiome Overview
Microbiome-Host Interaction
Human Microbiota Ecosystems
Role of Microbiota in Health and Disease
Effects of Probiotics and Prebiotics on gut microbiota
Microbiome Projects under development
Future of Microbiome
Hinderances for Microbiome as therapy
Challenges in studying the microbiome
Unmet needs of Microbiome
Pipeline Products Analysis
Microbiome-Number of Products (N) and Therapy Area
Microbiome Analysis by Therapy Area and Companies
Collaboration with Institutes
Number of Collaboration with Companies Year Wise
Number of Collaboration with Institutes Year wise
Collaboration with Companies
Collaboration with Institutes/Universities
Technology
Designation
Grants
Financing
Pipeline Therapeutics
Therapeutics under Development by Companies
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I and IND)
Comparative Analysis
Discovery and Pre-clinical stage Products
Comparative Analysis
Drug 1
Product Description
Research and Development
Product Development Activities
Product Description
Research and Development
Product Development Activities
Therapeutic Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Companies Planning for Future Development in Microbiome
Appendix
DelveInsight Consulting Services
About DelveInsight
Contact Us
Disclaimer
Executive Summary Snapshot
Microbiome Overview
Microbiome-Host Interaction
Human Microbiota Ecosystems
Role of Microbiota in Health and Disease
Effects of Probiotics and Prebiotics on gut microbiota
Microbiome Projects under development
Future of Microbiome
Hinderances for Microbiome as therapy
Challenges in studying the microbiome
Unmet needs of Microbiome
Pipeline Products Analysis
Microbiome-Number of Products (N) and Therapy Area
Microbiome Analysis by Therapy Area and Companies
Collaboration with Institutes
Number of Collaboration with Companies Year Wise
Number of Collaboration with Institutes Year wise
Collaboration with Companies
Collaboration with Institutes/Universities
Technology
Designation
Grants
Financing
Pipeline Therapeutics
Therapeutics under Development by Companies
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I and IND)
Comparative Analysis
Discovery and Pre-clinical stage Products
Comparative Analysis
Drug 1
Product Description
Research and Development
Product Development Activities
Product Description
Research and Development
Product Development Activities
Therapeutic Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Companies Planning for Future Development in Microbiome
Appendix
DelveInsight Consulting Services
About DelveInsight
Contact Us
Disclaimer
LIST OF TABLES
Table 1:Collaboration with Companies, 2017
Table 2:Collaboration with Institutes/Universities, 2017
Table 3: Microbiome technologies, 2017
Table 4: Designation, 2017
Table 5: Grants, 2017
Table 6: Financing, 2017
Table 7: Number of Products Under Development for Microbiome, 2017
Table 8: Number of Products under Development by Companies, 2017
Table 9: Mid Stage Products (Phase II),2017
Table 10: Early Stage Products (Phase I and IND), 2017
Table 11: Discovery and Pre-clinical Stage Products, 2017
Table 12: Number of Products Under Development for Microbiome, 2017
Table 13: Assessment by Combination Products, 2017
Table 14: Assessment by Route Of Administration, 2017
Table 15: Assessment by Stage and Route Of Administration, 2017
Table 16: Assessment by Molecule Type, 2017
Table 17: Assessment by Stage and Molecule Type, 2017
Table 1:Collaboration with Companies, 2017
Table 2:Collaboration with Institutes/Universities, 2017
Table 3: Microbiome technologies, 2017
Table 4: Designation, 2017
Table 5: Grants, 2017
Table 6: Financing, 2017
Table 7: Number of Products Under Development for Microbiome, 2017
Table 8: Number of Products under Development by Companies, 2017
Table 9: Mid Stage Products (Phase II),2017
Table 10: Early Stage Products (Phase I and IND), 2017
Table 11: Discovery and Pre-clinical Stage Products, 2017
Table 12: Number of Products Under Development for Microbiome, 2017
Table 13: Assessment by Combination Products, 2017
Table 14: Assessment by Route Of Administration, 2017
Table 15: Assessment by Stage and Route Of Administration, 2017
Table 16: Assessment by Molecule Type, 2017
Table 17: Assessment by Stage and Molecule Type, 2017
LIST OF FIGURES
Figure 1: Microbiome-Number of Products (N) and with Therapy Area, 2017
Figure 2: Number of Collaborations with Institute and Company, 2017
Figure 3: Number of Collaboration of Company, 2017
Figure 4: Number of Collaboration of Institute, 2017
Figure 5: Microbiome, number products and technology, 2017
Figure 6: Number of products and designation, 2017
Figure 7: Designation and year, 2017
Figure 8: Grants, 2017
Figure 9: Financing, 2017
Figure 10: Financing, 2017
Figure 11: Number of Products under Development for Microbiome, 2017
Figure 12: Mid Stage Products (Phase II), 2017
Figure 13: Early Stage Products (Phase I and IND), 2017
Figure 14: Discovery and Pre-clinical Stage Products, 2017
Figure 15: Assessment by Monotherapy Products,2017
Figure 16: Assessment Combination Products, 2017
Figure 17: Assessment by Route of Administration, 2017
Figure 18: Assessment by Stage and Route of Administration, 2017
Figure 19: Assessment by Molecule Type, 2017
Figure 20:Assessment by Stage and Molecule Type, 2017
Figure 1: Microbiome-Number of Products (N) and with Therapy Area, 2017
Figure 2: Number of Collaborations with Institute and Company, 2017
Figure 3: Number of Collaboration of Company, 2017
Figure 4: Number of Collaboration of Institute, 2017
Figure 5: Microbiome, number products and technology, 2017
Figure 6: Number of products and designation, 2017
Figure 7: Designation and year, 2017
Figure 8: Grants, 2017
Figure 9: Financing, 2017
Figure 10: Financing, 2017
Figure 11: Number of Products under Development for Microbiome, 2017
Figure 12: Mid Stage Products (Phase II), 2017
Figure 13: Early Stage Products (Phase I and IND), 2017
Figure 14: Discovery and Pre-clinical Stage Products, 2017
Figure 15: Assessment by Monotherapy Products,2017
Figure 16: Assessment Combination Products, 2017
Figure 17: Assessment by Route of Administration, 2017
Figure 18: Assessment by Stage and Route of Administration, 2017
Figure 19: Assessment by Molecule Type, 2017
Figure 20:Assessment by Stage and Molecule Type, 2017
